Deferasirox (ICL670) is clinically effective and generally well tolerated, and demonstrates dose-responsiveness [7]

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)775-776
Number of pages2
JournalBlood
Volume108
Issue number2
Publication statusPublished - Jul 15 2006

ASJC Scopus subject areas

  • Hematology

Cite this

Deferasirox (ICL670) is clinically effective and generally well tolerated, and demonstrates dose-responsiveness [7]. / Cappellini, Maria Domenica.

In: Blood, Vol. 108, No. 2, 15.07.2006, p. 775-776.

Research output: Contribution to journalArticle

@article{30bedba155754a6ab269db41e01ed079,
title = "Deferasirox (ICL670) is clinically effective and generally well tolerated, and demonstrates dose-responsiveness [7]",
author = "Cappellini, {Maria Domenica}",
year = "2006",
month = "7",
day = "15",
language = "English",
volume = "108",
pages = "775--776",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Deferasirox (ICL670) is clinically effective and generally well tolerated, and demonstrates dose-responsiveness [7]

AU - Cappellini, Maria Domenica

PY - 2006/7/15

Y1 - 2006/7/15

UR - http://www.scopus.com/inward/record.url?scp=33745941756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745941756&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33745941756

VL - 108

SP - 775

EP - 776

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -